Recent discussions on X about Tandem Diabetes Care (TNDM) have centered around the company’s latest developments, including a new FDA clearance for its t:slim X2 insulin pump with Control-IQ+ technology. Many users have expressed intrigue over the potential impact of this advancement on the company’s market position, especially as it integrates with ultra-rapid acting insulin options. The conversation also touches on analyst downgrades and lowered price targets, sparking debates about the stock’s growth trajectory.
Additionally, posts on X have highlighted concerns over a potential securities class action investigation, with some users questioning the implications of alleged misleading business information. Despite these concerns, there are also optimistic voices pointing to insider buying and strong cash flow as reasons for confidence in the company’s long-term potential. The mix of innovation and uncertainty keeps the dialogue lively and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Tandem Diabetes Care Congressional Stock Trading
Members of Congress have traded $TNDM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNDM stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 09/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Tandem Diabetes Care Insider Trading Activity
Tandem Diabetes Care insiders have traded $TNDM stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNDM stock by insiders over the last 6 months:
- LEIGH VOSSELLER (EVP & CHIEF FINANCIAL OFFICER) purchased 13,720 shares for an estimated $149,403
- JOHN F SHERIDAN (PRESIDENT & CEO) purchased 10,000 shares for an estimated $102,318
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tandem Diabetes Care Hedge Fund Activity
We have seen 149 institutional investors add shares of Tandem Diabetes Care stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OPHIR ASSET MANAGEMENT PTY LTD added 1,464,956 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,306,779
- GOLDMAN SACHS GROUP INC added 1,173,916 shares (+164.7%) to their portfolio in Q2 2025, for an estimated $21,881,794
- PARK WEST ASSET MANAGEMENT LLC removed 1,123,052 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $20,933,689
- FMR LLC removed 912,401 shares (-63.5%) from their portfolio in Q2 2025, for an estimated $17,007,154
- FRED ALGER MANAGEMENT, LLC removed 786,894 shares (-54.1%) from their portfolio in Q2 2025, for an estimated $14,667,704
- MILLENNIUM MANAGEMENT LLC added 741,488 shares (+325.8%) to their portfolio in Q2 2025, for an estimated $13,821,336
- TWO SIGMA INVESTMENTS, LP added 591,285 shares (+92.2%) to their portfolio in Q2 2025, for an estimated $11,021,552
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tandem Diabetes Care Analyst Ratings
Wall Street analysts have issued reports on $TNDM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/29/2025
- Oppenheimer issued a "Outperform" rating on 09/08/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 08/07/2025
- Stifel issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for Tandem Diabetes Care, check out Quiver Quantitative's $TNDM forecast page.
Tandem Diabetes Care Price Targets
Multiple analysts have issued price targets for $TNDM recently. We have seen 12 analysts offer price targets for $TNDM in the last 6 months, with a median target of $19.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $16.0 on 10/15/2025
- Joanne Wuensch from Citigroup set a target price of $15.0 on 10/07/2025
- William Plovanic from Canaccord Genuity set a target price of $24.0 on 09/29/2025
- Steven Lichtman from Oppenheimer set a target price of $22.0 on 09/08/2025
- Brooks O'Neil from Lake Street set a target price of $12.0 on 08/11/2025
- Matt Miksic from Barclays set a target price of $51.0 on 08/08/2025
- Shagun Singh from RBC Capital set a target price of $25.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
